Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy.
We propose the use of the Auger electron and positron-emitting generator 134Ce/134La (half-lives 3.16 d and 6.45 min) for radionuclide therapy. It combines emission of high-energy beta particles with Auger electrons. The high-energy beta particles have similar energies as those emitted by 90Y. Many cancer patients receiving radionuclide therapy have both bulk tumours, which are best treated with high-energy beta particles, and single spread cells or micrometastasis, which are preferably treated with low-energy electrons such as Auger and conversion electrons. Furthermore, the positron-emitting 134La can be used to study kinetics and dosimetry using PET. Production and PET performance were investigated and theoretical dosimetry calculations were made. PET resolution, recovery and quantitative accuracy were slightly degraded for 134La compared to 18F. 134Ce/134La absorbed doses to single cells were higher than absorbed doses from 90Y and 111In. Absorbed doses to spheres representing bulk tumours were almost as high as for 90Y, and a factor 10 higher than for 111In. Whole-body absorbed doses, based on kinetics of the somatostatin analogue octreotide, were higher for 134Ce/134La than for 90Y because of the 134La annihilation photons. This initial study of the therapeutic possibilities of 134Ce/134La is encouraging and justifies further investigations.
Lubberink
Mark
M
Uppsala University, Section of Biomedical Radiation Sciences, Rudbeck Laboratory, Sweden.
Lundqvist
Hans
H
Tolmachev
Vladimir
V
D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D004583:Electrons; D006801:Humans; D007554:Isotopes / Q000627:therapeutic use*; D007700:Kinetics; D007811:Lanthanum / Q000627:therapeutic use*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011874:Radiometry; D012542:Scattering, Radiation; D014055:Tomography, Emission-Computed / Q000379:methods*; D015019:Yttrium / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D002588:Cesium Radioisotopes; D007554:Isotopes; D015021:Yttrium Radioisotopes; D015019:Yttrium; D007811:Lanthanum